|
| Exchange Disseminated Time 05/08/2016 13:20:54 | On June 20, 2016, the Company had announced the acquisition of two ANDAs from Teva that were being divested by Teva as a pre-condition to its acquisition of Allergan's generic business. The acquisition of these ANDAs was contingent on the closing of the Teva-Allergan Generics transaction and approval by the US Federal Trade Commission.
Cadila Healthcare Ltd has now informed BSE that the transaction has now been completed and these ANDAs have been acquired by its 100% subsidiary, Zydus Worldwide DMCC. |
|
|